Co-founded by Medicxi and Jonny Finlay in 2020, Ottimo is developing Jankistomig, a PD1-VEGFR2 bi-functional antibody, designed as a dual-pathway, single agent, IgG therapy targeting immune checkpoint inhibition and angiogenesis in the treatment of cancer.  

By advancing this dual-pathway approach, Ottimo Pharma aims to improve cancer treatment outcomes and reduce overall healthcare burden.